Análise de impacto orçamentário: uma revisão prática de conceitos e aplicações para o gestor

Medeiros, Miguel de Araújo; Okumura, Lucas Miyake; Riveros, Bruno; Lucchetta, Rosa Camila; Rosim, Mariana; Nita, Marcelo Eidi

doi:10.21115/jbes.v10.n1.p75-9

Cited by 1 publication

(2 citation statements)

References 6 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total number of beneficiaries was 47,768,176. A total of 53.09% (25,358,355) of beneficiaries were female, of whom 22.87% (5,799,229) were children or adolescents (aged 0-19 years), 43.39% (11,001,855) were adult and fertile women (20-44 years), and 33.75% (8,557,271) were mature or elderly women (45-80 years or more) [34]. To this number, we applied the percentage of general contraceptive use (84.8%, as identified by Lago et al).…”

Section: Pharmacoeconomic Analysismentioning

confidence: 99%

See 1 more Smart Citation

Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system

Lopes da Silva Filho,

Luis Pereira Bueno,

Ramires

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

High rates of unplanned pregnancies persist despite pharmacological developments and advancements in contraceptive methods. Here, we demonstrate that the etonogestrel-releasing subdermal contraceptive implant (IMP-ETN) may be an appropriate and cost-effective alternative to levonorgestrel-releasing intrauterine systems (LNG-IUSs) for women in Brazil. For our pharmacoeconomic analysis, we reviewed the literature on IMP-ETN regarding its acceptance, eligibility criteria, choice, relations with age, adverse events and, finally, the unmet need in the fee-for-service private healthcare sector. We considered qualitative observations in combination with quantitative analysis and performed a deterministic sensitivity analysis to investigate whether this technology can be self-sustainable over a period of five years. The target population for this analysis comprised 158,696 women. Compared with the continued use of LNG-IUSs, adopting the IMP-ETN can result in a cost avoidance of $ 7.640.804,02 in the first year and $ 82,455,254.43 in five years. Disseminating information among physicians will promote this change and strengthen the potential cost avoided by private health system payers. These savings can be used to improve other healthcare programs and strategies. Moreover, the principles of care can be promoted by improving and adapting healthcare systems and expanding treatment and follow-up strategies. This would also provide support to women’s reproductive rights and improve their quality of life. Our results suggest that the IMP-ETN has a favorable cost-effectiveness profile. Given all its advantages and negative incremental cost impact over a period of five years, the IMP-ETN may be a more favorable alternative to LNG-IUSs. Therefore, it should be offered to beneficiaries with a private healthcare plan. This analysis overcomes previous barriers to the use of cost-benefit models, and our results may help balance decision-making by policymakers, technical consultants, and researchers.

show abstract

Section: Pharmacoeconomic Analysismentioning

confidence: 99%

“…In the private healthcare system, payments are predominantly based on the fee-for-service model, which is expensive. Therefore, it is important to identify more effective ways of allocating funds to ensure the sustainability of the private healthcare system [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%